<div class="container">

<table style="width: 100%;"><tr>
<td>sedative1000</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>FDA dataset for sedatives with 1000 adverse events</h2>

<h3>Description</h3>

<p>A 1001 by 11 data matrix of a contingency table processed from
the FDA Adverse Event Reporting System (FAERS) database. This dataset covers
a specific period from Q1 2021 to Q4 2023.
</p>


<h3>Usage</h3>

<pre><code class="language-R">sedative1000
</code></pre>


<h3>Format</h3>

<p>A data matrix with 1001 rows and 11 columns.
</p>


<h3>Details</h3>

<p>A 1001 by 11 data matrix of a contingency table from the FDA Adverse
Event Reporting System (FAERS) database, covering a specified period
from Q1 2021 to Q4 2023.
</p>
<p>The 1000 rows correspond to the AEs with the highest overall
frequency (row marginals) reported during the period and 1 row for Other AEs.
The reported AEs -
"Off label use" and "Drug ineffective" have been excluded.
</p>
<p>The dataset includes the following 10 columns: Clonazepam,
Dexmedetomidine, Diazepam, Diphenhydramine, Doxepin, Lorazepam,
Midazolam, Mirtazapine, Nitrazepam, Temazepam, and an Other column.
</p>
<p>The marginal totals for each column are as follows:
Clonazepam: 110,453, Dexmedetomidine: 4,262, Diazepam: 74,859
Diphenhydramine: 134,65, Doxepin: 11,795, Lorazepam: 101,969
Midazolam: 26,264, Mirtazapine: 54,273, Nitrazepam: 3,473,
Temazepam: 20,523, Other: 77,487,518
</p>
<p>Also refer to supplementary material of:
Ding, Y., Markatou, M., &amp; Ball, R. (2020). An evaluation of statistical
approaches to postmarketing surveillance. Statistics in Medicine, 39(7),
845-874
</p>
<p>for the data generation process.
The quarterly files can be found in
<a href="https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html">https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</a>.
</p>


<h3>Examples</h3>

<pre><code class="language-R">data(sedative1000)
head(sedative1000)

</code></pre>


</div>